US Stem Cell Inc (USRM)

[Poor Man -]

"As of May 4, 2016, there were 5,042,656 outstanding shares of the Registrant’s common stock, par value $0.001 per share. "

This company continues to bleed shares of stock, seriously diluting common shareholders. This is a doubling of common outstanding shares in just four months. And this is having a dramatic impact on the decline in USRM's stock price, and a corrosive effect on the value of every share held by anyone that owns stock in this company.

Continued losses are primarily funded via very expensive factoring of receivables and convertible notes that are typically converted into common shares.

USRM once again received a "Going Concern" footnote that raises concerns by the auditors about whether company has the resources to continue as a viable company. As quoted directly from the 10Q for March 31, 2016:

NOTE 2 – GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS

The accompanying condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements during three months ended March 31, 2016, the Company incurred net losses of $363,324 and used $62,073 in cash for operating activities. These factors among others may indicate that the Company will be unable to continue as a going concern for a reasonable period of time.

The Company's primary source of operating funds in 2015 and 2016 has been from revenue generated from sales with additional cash proceeds from the sale of common stock and the issuance of convertible and other debt. The Company has experienced net losses and negative cash flows from operations since inception, but expects these conditions to improve in 2016 and beyond as it develops it business model. The Company has stockholders' deficiencies at March 31, 2016 and requires additional financing to fund future operations.

The Company’s existence is dependent upon management’s ability to develop profitable operations and to obtain additional funding sources. There can be no assurance that the Company’s financing efforts will result in profitable operations or the resolution of the Company’s liquidity problems. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern.